Immunocore Holdings plc Selling General And Administrative Expense
Immunocore Holdings plc (IMCR) reported Selling General And Administrative Expense of GBP 33.88 million for the 3-month period ending 2023-06-30, per its 6-K filed 2023-08-10.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:SellingGeneralAndAdministrativeExpense · last filed 2023-08-10
- Immunocore Holdings plc selling general and administrative expense for the quarter ending 2023-06-30 was 33.88M GBP, a 80.13% increase year-over-year.
- Immunocore Holdings plc selling general and administrative expense for the quarter ending 2022-12-31 was 43.14M GBP, a 77.06% increase year-over-year.
- Immunocore Holdings plc selling general and administrative expense for the quarter ending 2022-09-30 was 11.66M GBP, a 41.82% decline year-over-year.
- Immunocore Holdings plc selling general and administrative expense for the quarter ending 2022-06-30 was 18.81M GBP.
| Period end | Selling General And Administrative Expense 3 month | Selling General And Administrative Expense 6 month | Selling General And Administrative Expense 9 month | Selling General And Administrative Expense 12 month |
|---|---|---|---|---|
| 2023-06-30 | 33.88M GBP 6-K · filed 2023-08-10 | 67.19M GBP 6-K · filed 2023-08-10 | ||
| 2022-12-31 | 43.14M GBP derived: 20-F 12 month − 6-K/A 9 month · filed 2023-03-01 | 54.81M GBP derived: sum of 2 quarters · filed 2023-03-01 | 73.62M GBP derived: sum of 3 quarters · filed 2023-08-10 | 93.72M GBP 20-F · filed 2023-03-01 |
| 2022-09-30 | 11.66M GBP 6-K/A · filed 2022-11-18 | 30.47M GBP derived: sum of 2 quarters · filed 2023-08-10 | 50.58M GBP 6-K/A · filed 2022-11-18 | |
| 2022-06-30 | 18.81M GBP 6-K · filed 2023-08-10 | 38.92M GBP 6-K · filed 2023-08-10 | ||
| 2021-12-31 | 24.37M GBP derived: 20-F 12 month − 6-K/A 9 month · filed 2023-03-01 | 44.41M GBP derived: sum of 2 quarters · filed 2023-03-01 | 88.40M GBP 20-F · filed 2023-03-01 | |
| 2021-09-30 | 20.05M GBP 6-K/A · filed 2022-11-18 | 64.03M GBP 6-K/A · filed 2022-11-18 | ||
| 2020-12-31 | 45.74M GBP 20-F · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |